Overview

A Study of ISIS 678354 Administered to Participants With Severe Hypertriglyceridemia

Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy of ISIS 678354 as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
Phase:
Phase 3
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.